TY - JOUR
T1 - APOL1 kidney disease
T2 - conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
AU - Ojo, Akinlolu O.
AU - Adu, Dwomoa
AU - Bramham, Kate
AU - Freedman, Barry I.
AU - Gbadegesin, Rasheed A.
AU - Ilori, Titilayo O.
AU - Jefferson, Nichole
AU - Olabisi, Opeyemi A.
AU - Susztak, Katalin
AU - Young, Bessie A.
AU - Cheung, Michael
AU - King, Jennifer M.
AU - Grams, Morgan E.
AU - Jadoul, Michel
AU - Ulasi, Ifeoma I.
AU - Afonope, Angela Opokua
AU - Akyea-Darkwah, Godfred
AU - Albright, Jaime
AU - Albright, Joshua
AU - Antwi, Sampson
AU - Ashuntantang, Gloria
AU - Boima, Vincent
AU - Campbell, Kirk N.
AU - Darkwah, Ewurabena Aniniwa
AU - Ezeibe, Victor
AU - Fabian, June
AU - Fisher, Lori Ann
AU - Friedman, David J.
AU - Gibson, Keisha L.
AU - Greer, Raquel Charles
AU - Hidaka, Sumi
AU - Jefferson, Taler B.K.
AU - Lentine, Krista L.
AU - Limou, Sophie
AU - Martin, Dominique E.
AU - Mott, Kevin
AU - Moxey-Mims, Marva M.
AU - Naicker, Saraladevi
AU - Miranda de Menezes Neves, Precil Diego
AU - Niang, Abdou
AU - Noronha, Irene L.
AU - Parekh, Rulan S.
AU - Parsa, Afshin
AU - Rayner, Brian L.
AU - Sanna-Cherchi, Simone
AU - Sedor, John R.
AU - Servais, Aude
AU - Shingwenyana, Barry
AU - Sintim, Bernard
AU - Speller, Junelle P.
AU - Kiswaya, Ernest Sumaili
AU - Ulasi, Ifeoma I.
AU - Vianna, Fernanda Sales Luiz
N1 - Publisher Copyright:
© 2025 Kidney Disease: Improving Global Outcomes (KDIGO)
PY - 2025/11
Y1 - 2025/11
N2 - In people of African ancestry, apolipoprotein L1 gene (APOL1) variants have been identified as causing increased risk of progressive chronic kidney disease (CKD). In April of 2024, Kidney Disease: Improving Global Outcomes (KDIGO) convened a Controversies Conference on APOL1 Kidney Disease in Accra, Ghana. The goals of the conference were to review and discuss current evidence and controversies on APOL1 kidney disease, including naming, epidemiology, pathophysiology, APOL1 testing, treatment, and future research needs. Participants considered various terminologies for diseases related to APOL1 risk variants (such as APOL1-mediated or -induced kidney disease) and had highest support for using APOL1 kidney disease to describe kidney pathologies associated with the APOL1 G1 and G2 risk variants. Clinically, the term APOL1 kidney disease can be used on its own or as an overall category of kidney disease, with further specification added as needed (for example, APOL1 kidney disease, focal segmental glomerulosclerosis). Given that there are currently no established treatments for APOL1 kidney disease, and APOL1 genotype results are not by themselves actionable, there is insufficient evidence to guide recommendations for APOL1 population screening or routine testing. However, genotyping can be an important clinical consideration for individuals to inform risk stratification, frequency of follow-up, living kidney donation, as well as clinical trial eligibility. Key areas of need and strategies for future research were delineated and are reported here.
AB - In people of African ancestry, apolipoprotein L1 gene (APOL1) variants have been identified as causing increased risk of progressive chronic kidney disease (CKD). In April of 2024, Kidney Disease: Improving Global Outcomes (KDIGO) convened a Controversies Conference on APOL1 Kidney Disease in Accra, Ghana. The goals of the conference were to review and discuss current evidence and controversies on APOL1 kidney disease, including naming, epidemiology, pathophysiology, APOL1 testing, treatment, and future research needs. Participants considered various terminologies for diseases related to APOL1 risk variants (such as APOL1-mediated or -induced kidney disease) and had highest support for using APOL1 kidney disease to describe kidney pathologies associated with the APOL1 G1 and G2 risk variants. Clinically, the term APOL1 kidney disease can be used on its own or as an overall category of kidney disease, with further specification added as needed (for example, APOL1 kidney disease, focal segmental glomerulosclerosis). Given that there are currently no established treatments for APOL1 kidney disease, and APOL1 genotype results are not by themselves actionable, there is insufficient evidence to guide recommendations for APOL1 population screening or routine testing. However, genotyping can be an important clinical consideration for individuals to inform risk stratification, frequency of follow-up, living kidney donation, as well as clinical trial eligibility. Key areas of need and strategies for future research were delineated and are reported here.
KW - chronic kidney disease
KW - genetic testing
KW - glomerulosclerosis
UR - https://www.scopus.com/pages/publications/105013264489
UR - https://www.scopus.com/pages/publications/105013264489#tab=citedBy
U2 - 10.1016/j.kint.2025.05.017
DO - 10.1016/j.kint.2025.05.017
M3 - Article
C2 - 40582702
AN - SCOPUS:105013264489
SN - 0085-2538
VL - 108
SP - 763
EP - 779
JO - Kidney international
JF - Kidney international
IS - 5
ER -